Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Oral exposure:

Potassium Niobate was fed to three groups of 5 weaned, male rats each at dietary levels of 0, 0.10 and 1 % for a duration of 7 weeks. No abnormal gross findings were noted in these rats. Kidney weights and kidney weight to body weight ratios were within control limits. Histopathological examination of sections of the liver, kidney, or spleen revealed no tissue changes that could be attributed to the ingestion of potassium niobate.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records
Reference
Endpoint:
repeated dose toxicity: oral, other
Type of information:
experimental study
Adequacy of study:
supporting study
Study period:
1965, July - August
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
documentation insufficient for assessment
Qualifier:
no guideline available
Principles of method if other than guideline:
- Principle of test: To investigate the sub-acute oral toxicity of Potassium Niobate
- Short description of test conditions: - Three groups (same number and sex) were fed diets containing 0, 0.10 and 1 % Potassium Niobate.
- Parameters analysed / observed: Body weight, histopathology of the liver, spleen, and kidney
GLP compliance:
no
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source of test material: Union Carbide Metals Co., Niagara Falls, N.Y.
Species:
rat
Sex:
male
Route of administration:
oral: feed
Vehicle:
not specified
Details on oral exposure:
DOSING SOLUTIONS: 0, 0.10 and 1.0% Potassium Niobate
Duration of treatment / exposure:
7 weeks
Dose / conc.:
1 mg/kg diet
Dose / conc.:
10 mg/kg diet
No. of animals per sex per dose:
three groups of 5 males weanling rats each
Control animals:
yes, concurrent no treatment
Observations and examinations performed and frequency:
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
Sacrifice and pathology:
GROSS PATHOLOGY: Yes

Clinical signs:
not examined
Mortality:
mortality observed, treatment-related
Description (incidence):
- A total of 4 deaths occurred and two of these occurred in the control group
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
no effects observed
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
Histopathological examination of sections of the liver, kidney, or spleen revealed no tissue changes that could be attributed to the ingestion of potassium niobate
Histopathological findings: neoplastic:
not examined
Other effects:
not examined
Key result
Dose descriptor:
NOAEL
Effect level:
10 mg/kg diet
Based on:
test mat.
Sex:
male
Conclusions:
Potassium niobate was fed to three groups of 5 weaned, male rats each at dietary levels of 0, 0.10 and 1 % for a duration of 7 weeks. No treatment related effects were observed.
Executive summary:

Potassium niobate was fed to three groups of 5 weaned, male rats each at dietary levels of 0, 0.10 and 1 % for a duration of 7 weeks. Histopathological examination of sections of the liver, kidney, or spleen revealed no tissue changes that could be attributed to the ingestion of potassium niobate.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Two studies (obtained from published data) are available using potassium niobate via intravenous (i.v.) and intraperitoneal (i.p.) injections. Renal damage in rats and dogs after a single i.v. application of 30 mg/kg bw of niobium as potassium niobate was reported by Wong and Downs (1966). Daily i.p. injections of potassium niobate (pH 12.2) at doses of 10, 29, 57 and 95 Nb/kg was reported to cause renal injury (Downs M.S. et al., 1965).

Justification for classification or non-classification

In an oral feeding study with rats no adverse effect was reported in the liver, kidney, or spleen. Therefore, no classification was warranted. Although the i.v. and i.p. route of exposure resulted in renal injury in dogs and rats, these routes are not considered relevant for classification and labelling.